Sveitsi - ranska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - sunitinibum - gélules - sunitinibum 12.5 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium, povidonum, magnesii stearas, kapselhülle: e 172 (rubrum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - cytostatique - synthetika

Sveitsi - ranska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - sunitinibum - gélules - sunitinibum 25 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium, povidonum, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - cytostatique - synthetika

Sveitsi - ranska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - sunitinibum - gélules - sunitinibum 50 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium, povidonum, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - cytostatique - synthetika

Euroopan unioni - ranska - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agents antinéoplasiques - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Sveitsi - ranska - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - sunitinibum - gélules - sunitinibum 12.5 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium max. 0.20 mg, povidonum k 30, magnesii stearas, kapselhülle: e 172 (rubrum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - cytostatique - synthetika

Sveitsi - ranska - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - sunitinibum - gélules - sunitinibum 25 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium max. 0.41 mg, povidonum k 30, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - cytostatique - synthetika

Sveitsi - ranska - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - sunitinibum - gélules - sunitinibum 50 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium max. 0.81 mg, povidonum k 30, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - cytostatique - synthetika

Belgia - ranska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - sunitinib 12,5 mg - gélule - 12,5 mg - sunitinib 12.5 mg - sunitinib

Belgia - ranska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - sunitinib 25 mg - gélule - 25 mg - sunitinib 25 mg - sunitinib

Belgia - ranska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - sunitinib 37,5 mg - gélule - 37,5 mg - sunitinib 37.5 mg - sunitinib